Project Grant R01HL173436
Award Date
6/15/25
Completion Date
3/31/29
Dollars Obligated
$780K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $552,413 to Thomas Jefferson University (Sidney Kimmel Medical College) for research focused on understanding platelet and megakaryocyte function through the use of short inhibitory RNAs (siRNAs). The key goals are to: 1) investigate siRNA-mediated in vivo knockdown of the P2Y12 receptor to modulate thrombosis without compromising hemostasis; 2) investigate...
This $225,600 project grant awarded by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to engineer a lab-on-a-particle platform to measure platelet function. The project will synthesize peptide-functionalized hydrogel microparticles to serve as individual test sites for studying platelet adhesion, activation, aggregation, and contraction. The research will utilize immobilized and suspended particle assays to measure...
This federal Project Grant award of $445,708 from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to define the role of platelet ABO(H) blood group antigens in hemostasis (bleeding) and thrombosis (blood clots). The overarching goal is to gain mechanistic insight into how platelet ABO blood type affects binding to von Willebrand factor, a key regulator of platelet function and blood clotting. The...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $465,000 in funding to Bloodworks, a non-profit organization in Seattle, Washington. The grant supports research to investigate the mechanisms by which chronic inflammation disrupts autophagy and mitophagy processes in platelets and red blood cells of individuals with sickle cell disease. The research aims to elucidate how this leads to the accumulation of...
This $5,154,906 five-year Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports a coordinated, multi-disciplinary investigation into the molecular mechanisms underlying clinically important immune-mediated thrombocytopenic and thrombotic disorders. The overarching objectives are to build a deeper understanding of immunological insults that lead to thrombocytopenia and related pathophysiological...
This federal Project Grant award of $930,481 from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to support research on the roles of synthetic glycosaminoglycan mimetics (NSGMs) in regulating megakaryopoiesis and thrombopoiesis, which are processes involved in platelet production. The award was made to the University of North Texas, a Hispanic-Serving Institution, and will fund a 3-year research project focused on:...
This Project Grant award of $528,179 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to investigate the systemic effects of ischemia training on the reprogramming of bone marrow-derived monocytes and the role of the DHCR24 enzyme in regulating monocyte-endothelial cell interactions to improve neovascularization in peripheral arterial disease (PAD) and critical limb ischemia (CLI). The key research objectives are to: 1) determine...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $693,423 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Baylor College of Medicine. The grant will fund the development and validation of a disposable microfluidic device capable of efficiently purifying platelets for pediatric and neonatal transfusions. The project aims to optimize the Controlled Incremental Filtration (CIF) technology to remove contaminants from platelet units while preserving...
This $685,884 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research to investigate the role of the C1 inhibitor protein in regulating coagulation and thrombosis, with the goal of identifying new therapeutic approaches for preventing venous thromboembolism. The research aims to: 1) Evaluate the molecular mechanisms by which C1 inhibitor regulates coagulation and venous thrombosis in mice, 2) Assess the impact of...
This Project Grant award, funded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research), is focused on investigating the role of the PAR1/IL-17 signaling axis in the development and progression of chronic thromboembolic pulmonary hypertension (CTEPH). The primary objectives are to determine if this signaling pathway contributes to abnormal cell phenotypes in chronic thrombus, as well as to evaluate the activity of PAR1 and IL-17 signaling in different...